ProQuest logo

ProQuest

North America, Michigan, United States, Ann Arbor

Description

ProQuest is a software solution that provides data and analytics to academic, research, and national institutions.

Investor Profile

ProQuest has made 3 investments, with 0 in the past 12 months and 67% as lead.

Stage Focus

  • Series Unknown (33%)
  • Series B (33%)
  • Seed (33%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Biopharma
  • Health Diagnostics
  • Pharmaceutical
  • Edtech
  • Information Services
  • Software
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does ProQuest frequently co-invest with?

Seaflower Ventures
North America, Massachusetts, United States, Waltham
Co-Investments: 1
CH
North America, Pennsylvania, United States, Radnor
Co-Investments: 1
Canaan Partners
North America, California, United States, Menlo Park
Co-Investments: 1
NewSpring Ventures
North America, Pennsylvania, United States, Radnor
Co-Investments: 1
Sprout Group
North America, New York, United States, New York
Co-Investments: 2
HealthCap
Europe, Stockholms Lan, Sweden, Stockholm
Co-Investments: 1
TL Ventures
North America, Pennsylvania, United States, Wayne
Co-Investments: 1
Bessemer Venture Partners
North America, California, United States, San Francisco
Co-Investments: 1

What are some of recent deals done by ProQuest?

Underline Science

New York, New York, United States

The world’s first live-streaming and digital library platform for cutting-edge scientific and medical content.

EdTechInformation ServicesSoftware
SeedSep 10, 2020
Amount Raised: $1,500,000
Affymax

Cupertino, California, United States

Affymax is a biopharmaceutical company.

BiopharmaBiotechnologyHealth Care
Series UnknownMar 3, 2009
Amount Raised: $41,999,999
Sopherion Therapeutics

East Brunswick, New Jersey, United States

Sopherion has the US and Canadian rights to this liposomal nanotechnology that targets the tumor vasculature.

BiotechnologyHealth CareHealth DiagnosticsPharmaceutical
Series BSep 20, 2004
Amount Raised: $47,000,000